As previously announced, the company has granted to the underwriter a 30-day option to purchase up to 7,031,250 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
H.C. Wainwright and Co. acted as the sole book-running manager for the offering.
The gross proceeds to the company from the offering are USD 75m, before deducting underwriting discounts and commissions and other offering expenses.
The company said it plans to use the net proceeds from this offering for working capital and general corporate purposes.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a portfolio of small-molecule anti-cancer therapeutics.
The company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia.
The company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Metagenomi Adds Immuno-oncology Clinical Research Experts to its Scientific Advisory Board
Vividion Raises USD 135m in Series C Financing
NovellusDx Establishes Fore Biotherapeutics US as its Operating company in the United States
Dhingra Named Chairman of the Board of Directors at Lava Therapeutics
Bristol Myers Squibb announces cell therapy manufacturing facility construction
Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
LARVOL names Mark Lagunowich as vice president, Global Sales
ESSA Pharma Inc completes underwritten public offering of common shares
ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix
Dr. Reddy's Laboratories Launches Lansoprazole DR Orally Disintegrating Tablets in the US Market